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Background. Recombinant T-cell receptor ligand 1000 (RTL1000) is a single-chain protein construct containing the outer two
domains of HLA-DR2 linked to myelin-oligodendrocyte-glycoprotein- (MOG-) 35–55 peptide. Analogues of RTL1000 induce
T-cell tolerance, reverse clinical and histological disease, and promote repair in experimental autoimmune encephalomyelitis
(EAE) in DR2 transgenic, C57BL/6, and SJL/J mice. Objective. Determining the maximum tolerated dose, safety, and tolerability
of RTL1000 in multiple sclerosis (MS) subjects. Methods. This was a multicenter, Phase I dose-escalation study in HLA-DR2+
MS subjects. Consecutive cohorts received RTL1000 doses of 2, 6, 20, 60, 200, and 100mg, respectively. Subjects within each
cohort randomly received a single intravenous infusion of RTL1000 or placebo at a 4:2 ratio. Safety monitoring included clinical,
laboratory, and brain magnetic resonance imaging (MRI) evaluations. Results. Thirty-four subjects completed the protocol. All
subjects tolerated the 2–60mg doses of RTL1000. Doses ≥100mg caused hypotension and diarrhea in 3 of 4 subjects, leading to
discontinuationoffurtherenrollment. Conclusions.ThemaximumtolerateddoseofRTL1000inMSsubjectsis60mg,comparable
to eﬀective RTL doses in EAE. RTL1000 is a novel approach for MS treatment that may induce immunoregulation without
immunosuppression and promote neural repair.
1.Introduction
ThepathogenesisofMSlikelyinvolvesincreasedCD4+ T-cell
responses directed against myelin antigens, including myelin
oligodendrocyte glycoprotein (MOG) [1]. Myelin-reactive
T - c e l l sa r ep r e s e n te v e ni nh e a l t h yc o n t r o l sb u ta r ea c t i v a t e d
andoccurathigherfrequenciesinMSsubjects[2],duepossi-
bly to escape from tolerance mechanisms. An elusive goal for2 Autoimmune Diseases
the treatment of MS is the development of therapies that can
reestablish tolerance without causing immunosuppression.
Encephalitogenic CD4+ T-cells respond to speciﬁc
myelin peptides complexed with major histocompatibility
(MHC) class II molecules on antigen-presenting cells (APC).
Ligation of the CD4+ T-cell receptor in combination with
costimulatory molecules results in activation of autoreactive
T-cells that migrate into the central nervous system (CNS)
and trigger an inﬂammatory cascade, resulting in tissue
injury and clinical disease. A variety of approaches can block
antigen-speciﬁc T-cell activation, including intravenous
exposure to high doses of free antigen [3], presentation of
antigen by modiﬁed APCs [4], oral ingestion of antigen
[5, 6], or injection of MHC/antigen complexes [7, 8].
Injection of soluble MHC/antigen complexes suppresses
clinical and histological signs of experimental autoimmune
encephalomyelitis (EAE) [9, 10]. This strategy utilizes an
encephalitogenic myelin peptide bound by autologous MHC
class II alleles, inducing anergy after T-cell engagement of
the soluble MHC/antigen complex in the absence of costim-
ulatory molecules [11]. This approach for treatment of MS
became practical by our development of recombinant single
chain, two domain MHC class II molecules linked covalently
to autoantigenic peptides [12]. These recombinant T-cell
receptor ligands (RTLs) proved highly eﬀective for reversing
established EAE in several diﬀerent rodent models [13–16].
T od e v e l o pa nR T Lp o t e n t i a l l ye ﬀective for MS, we combined
the immunodominant MOG-35-55 peptide with the β1-α1
domains of HLA-DR2 [17], the highest genetic risk factor
that occurs in ∼60% of North American and Northern
European MS patients [18, 19]. We further demonstrated
that this RTL construct, designated as RTL1000, was highly
eﬀective at suppressing and treating MOG-35-55 peptide-
induced EAE in DR2 transgenic mice [14, 20].
To determine the maximum tolerated dose of RTL1000
in subjects with MS, we performed a multicenter, Phase 1,
placebo-controlled, single dose-escalation study. This study
demonstrated that a dose of 60mg of RTL1000 was well
tolerated and importantly is comparable to single doses of
RTL1000 that are highly therapeutic in DR2 transgenic mice
with MOG-35-55-induced EAE.
2.MaterialsandMethods
2.1. Subjects. This study was conducted under an FDA
approved IND (no. 100128) by Artielle ImmunoTherapeu-
tics, Inc., Tigard, OR, approved by Institutional Review
Boards from the six participating institutions (Oregon
Health & Science University, Portland, OR; Swedish Neuro-
science Institute, Seattle, WA; University of Kansas Medical
Center, Kansas City, KS; University School of Medicine, Indi-
ana University MS Center, Indianapolis, IN; Yale University,
New Haven, CT; University of Maryland School of Medicine,
Baltimore, MD) and registered at http://www.clinicaltrials
.gov/ (NCT00411723). All subjects gave informed consent
before entering the study. Qualiﬁed subjects met the follow-
ing inclusion/exclusion criteria: deﬁnite diagnosis of MS by
McDonald criteria [21]; conﬁrmed diagnosis of RRMS or
SPMS; age 18–65; Expanded Disability Status Scale (EDSS)
of 0.0 to 6.5; no clinical exacerbations within the 8 weeks
before administration of study drug; HLA-DR2 positive; not
pregnant or breastfeeding and using an acceptable form of
birth control; no exposure to any investigational agent or use
of recombinant interferon beta, glatiramer acetate, or sys-
temic corticosteroids in the past 4 weeks; no treatment
with a monoclonal antibody, natalizumab, or systemic im-
munosuppressants, including azathioprine, mycophenolate
mofetil, methotrexate, cladribine, cyclophosphamide, or mi-
toxantrone in the past 6 months; no total lymphoid irradia-
tion or bone marrow transplant at any time.
2.2. Study Design. This was a multicenter, double-blind,
placebo-controlled Phase 1 dose-escalating trial with six
consecutive treatment cohorts. The study was designed to
enrollsixMSsubjectspercohortusingaratioof4:2subjects
randomly assigned to receive a single dose of RTL1000 or
placebo, respectively. Subjects were admitted to an inpatient
research unit, received the study drug by intravenous (IV)
infusion over approximately 1 hour (Cohorts 1–4) or 2
hours (Cohorts 5 and 6). Subjects were observed during the
infusion and for 24hrs afterward. To further evaluate safety,
subjects were evaluated weekly for 28 days and again on
month 3 when they exited the study.
2.2.1. Endpoints. The primary endpoints of the study were
safety and determination of the maximum tolerated dose
(MTD) of a single IV infusion of RTL1000. The secondary
endpointwastoevaluatepharmacokinetics(PK)ofRTL1000
in a subset of subjects. Safety laboratory parameters included
electrocardiogram (EKG), vital signs, blood chemistries,
complete blood count, and antibodies to RTL1000, MOG-
35-55 peptide, and HLA-DR2. Clinical safety parameters
included medical and neurologic history and examination,
EDSS, 25-foot timed walk, 9-hole peg test, gadolinium-
enhanced brain MRI, and adverse events. Clinical assess-
mentswereperformedbysiteinvestigatorswhoweremasked
to the treatment assignment of subjects.
Adverse events and laboratory results were graded ac-
cording to the common terminology criteria for adverse
events, CTCAE v3.0. Subjects were closely monitored for
allergic or infusion reactions during the administration of
the product. An independent Data Safety Monitoring Board
(DSMB), comprised of two neurologists and a statistician,
reviewed blinded data at the completion of each cohort and
gave permission to initiate enrollment in the next cohort if
prespeciﬁed safety criteria were met.
2.2.2. Procedure Time Points. Subjects enrolled in the trial
underwent neurological examination and MRI scan at
baseline. On Day 0, just prior to infusion of RTL1000
or placebo, blood was drawn and plasma frozen for later
evaluationofantibody titersandconcentrationsofRTL1000.
Additional blood was drawn during and immediately after
theinfusionforPKevaluationofRTL1000levelsinplasmain
subjects who agreed to participate in the PK substudy. After
completion of the infusion, subjects underwent brain MRIAutoimmune Diseases 3
(Day 28), neurological examination (Day 28 and 3 months)
and antibody levels (Day 28 and 3 months).
2.2.3. RTL1000 and Placebo. RTL1000 was supplied as a
sterile liquid for IV infusion. Each 10mL vial contained
10mgRTL1000ataconcentrationof1mg/mLin20mMTris
buﬀer at pH8.5. The placebo consisted of Tris buﬀer solution
only, which was visually indistinguishable from the solution
with RTL1000. RTL1000 or placebo was infused over 1 hour
for doses of ≤60mg and 2 hours for doses of 100–200mg.
RTL1000 or placebo labeled in a blinded fashion with the
subject randomization number was shipped for each subject.
2.2.4. Clinical and Safety Monitoring. Safety and tolerability
were evaluated throughout the study by monitoring subject
chemistry and hematology laboratory panels, EKGs, MRIs,
neurologic and physical examinations, EDSS, 25-ft timed
walk and 9-hole peg test.
2.2.5. MRI Procedures. Using a standardized procedure,
brain MRIs were performed at baseline and Day 28. All
study MRIs were screened at the individual study sites for
incidental and nonstudy ﬁndings. MRIs were transferred
electronically to a central reading center at the Portland VA
Medical Center under the direction of Dr. Jack Simon. All
MRI analyses were performed blinded to treatment alloca-
tion. The following assessments were made: total number of
gadolinium enhancing lesions on the baseline and D28 scans
and new and persistent gadolinium enhancing lesions and
new and enlarging T2 hyperintensities on the D28 scan. The
frequency of subjects with active scans (deﬁned as those with
≥1 gadolinium enhancing lesions) in each cohort was also
determined on the baseline and D28 MRI.
2.3. Assessment of Immunosuppression. Six subjects agreed to
participate in an immunology substudy. For these subjects,
peripheral blood mononuclear cells (PBMCs) were collected
prior to infusion of drug or placebo and at 14 and 28 days
after infusion and were stored in liquid nitrogen. Samples
from each time point were cultured and analyzed as a group
for reactivity to anti-CD3 mAb. Brieﬂy, 250,000 PBMC were
cultured in triplicate wells in RPMI 1640 with 1% pooled
human serum in the presence of 1μg anti-CD3 mAb or
buﬀer control. Culture supernatants were collected after 48h
and sent to AssayGate, Inc. (Ijamsville, MD) for analysis
of IL-1α, IL-6, IL-8, IL-10, IL-12(p40), IL-15, IL-17, IP-10,
MCP-1, MIP-1α,M I P - β,a n dT N F - α.
2.4. Statistical Analyses
2.4.1. Study Conduct, Baseline Characteristics, and Safety.
Descriptive statistics were used to summarize study conduct,
baseline measures, and safety (including RRMS disease
parameters). Adverse events were tabulated by dose cohort,
system organ class, preferred term, according to frequency,
severity, and investigator-determined relationship to study
drug. Basic descriptive statistics for antibody O.D.s including
mean ± SD were carried out for each sample collection
time point, and P values were derived by applying Fisher’s
exact test comparing the ratio of positive subjects receiving
RTL1000 versus placebo at month 1 or month 3 versus
baseline.
3. Results
3.1. Trial Proﬁle. Between January, 2007, and November,
2008, after signing the informed consent, 108 MS subjects
were initially assessed for eligibility and screened for HLA-
DR2 (Figure 1). Of these, 50 did not meet inclusion criteria
and 20 declined to participate. Of the remaining 38 subjects,
34 were randomized as described (Table 1). Four subjects
who met entry criteria were not randomized as the study was
stopped before they were randomized. All 34 treated subjects
completed the protocol.
Upon the recommendation of the DSMB, Cohort 2 was
repeated because one subject receiving 6mg study drug
developed chest pain. No adverse events were encountered
with a second cohort (2A) receiving the same dose. Cohort
5, which received 200mg, was stopped because two of the
three subjects receiving study drug experienced signiﬁcant
infusion-related adverse events. With permission of the
DSMB, Cohort 6 was initiated to receive an intermediate
dose (100mg), but treatment of this cohort was stopped
after the ﬁrst subject, who received study drug, experienced
adverse events similar to those observed in Cohort 5.
3.2. Safety and Maximum Tolerated Dose
3.2.1. Adverse Events. No serious adverse events occurred
during the study. RTL1000 infusions were well tolerated at
dosesof60mgorless.Theoverallincidenceofadverseevents
was similar in subjects receiving RTL1000 versus placebo
(87.0% RTL1000, 81.8% placebo). In subjects receiving
RTL1000 at doses of 60mg or less, adverse events did not
diﬀer between subjects receiving study drug and placebo
aside from the occurrence of chest pain in one subject
receiving 6mg in Cohort 2. This subject experienced chest
pain during the infusion that resolved and did not delay
discharge; the event was assessed as treatment related by
the site investigator; no cardiac or pulmonary etiology was
found, despite extensive in-hospital workup. Chest pain did
notoccurinothersubjectsreceivingRTL1000.Dose-limiting
adverse events occurred in subjects receiving doses above
60mg.Onesubjectreceiving100mgofRTL1000hadnausea,
vomiting, diarrhea, headache, chills, and decreased blood
pressure. Two of the three subjects who received 200mg
of RTL1000 experienced similar reactions, and these two
subjects also experienced tachycardia, fever, and an increased
neutrophil count. All events resolved within 24hr and
discharge from the inpatient research unit was not delayed.
Based on these adverse events, the DSMB determined that
the MTD had been achieved and was 60mg. Two of 23
subjects (9%; mean annualized relapse rate of 0.35) receiving
RTL1000 and one of 11 subjects (9%; mean annualized
relapse rate of 0.36) receiving placebo had MS exacerbations4 Autoimmune Diseases
Consort 2010 ﬂow diagram
Enrollment
Allocation
Analysis
Assessed for eligibility
(n = 108)
Allocated to intervention (n = 23)
• Received allocated intervention (n = 23)
• Did not receive allocated intervention (n = 0)
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
Analysed (n = 23)
• Excluded from analysis (n = 0)
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
Analysed (n = 11)
• Excluded from analysis (n = 0)
Allocated to intervention (n = 11)
• Received allocated intervention (n = 11)
• Did not receive allocated intervention (n = 0)
Excluded (n = 74)
• Not meeting inclusion criteria (n = 50)
• Declined to participate (n = 20)
Randomized (n = 34)
Followup
Figure 1: Flow chart of subject enrollment and treatment. One hundred eight MS subjects were screened, with 67 testing positive for
expression of HLA-DR2. Of these, 29 failed additional screening (did not meet EDSS requirement, were taking exclusionary drugs, or had a
surgical procedure) or declined entry and 38 were enrolled in the trial.
during the follow-up period; the treating physicians believed
that none of these events were treatment related and the
DSMB agreed with this assessment.
Adverse events did not lead to subject withdrawal
from the study. The most common adverse events in sub-
jects receiving RTL1000 were headache (34.8%), vomiting
(30.4%), and nausea (26.1%) and were assessed as treatment
related in 26.1%, 26.1%, and 21.7% of subjects, respectively.
Subjects receiving placebo had lower frequencies of these
side eﬀects: headache (27.3%), vomiting (0%), and nausea
(9.1%). While headache, vomiting, and nausea at Grade 1
levels occurred across all dose groups, nausea and vomiting
were more likely to be Grade 2 in the 100 and 200mg dose
groups.
3.2.2. RTL1000 Did Not Increase MS-Related Disease Activity.
In this study RTL1000 treatment did not worsen MS as
assessed by clinical safety endpoints (relapses, EDSS, timed
walk,9-holepegtest)andMRI.AsshowninTable 2,thetotal
number of gadolinium enhancing lesions and the number
of new gadolinium enhancing and new and enlarging T2
hyperintensities did not increase signiﬁcantly in any of
the cohorts receiving RTL1000. As shown in Figure 2, the
frequency of subjects with active MRI scans in the RTL1000
cohorts decreased in three cohorts and remained stable in
one cohort following treatment. In the 20mg cohort, none
of the subjects had active scans at baseline and at D28 one
subject had developed one gadolinium enhancing lesion.
Frequency of subjects receiving placebo with active scans
remained stable. Thus, there was no evidence of increased
disease activity following RTL1000 administration.
3.2.3. RTL1000 Doses within the MTD Range in Subjects with
MS Have Potent Therapeutic Activity at Comparable Doses in
Mice with EAE. Based on body surface area measurements,
the comparable dose of RTL1000 for treatment of EAE in
mice is ∼250X less than the dose used in humans [22]. Thus,
60mg of RTL1000 in MS subjects is comparable to 240μgi n
mice (Figure 3 inset). As shown in Figure 3,as i n g l el o w e r
dose of 100μg of the mouse MOG homologue of RTL1000
(equivalent to a 25mg dose in humans) was suﬃcient toAutoimmune Diseases 5
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Figure 2: RTL1000 dose and fraction of subjects with gadolinium
enhancinglesionsatbaselineand28daysafterinfusion:gadolinium
enhancing lesions were scored for each subject at baseline (before
dose) and 28 days after infusion of RTL1000 or placebo and the
percentage of subjects with ≥1 GAD-enhancing lesion is indicated
for each dosing group.
produce sustained reversal of paralytic signs of MOG-35-55-
induced EAE in DR2 transgenic mice over 28 days. These
data demonstrate the potent clinical eﬃcacy of RTL1000
homologue in EAE at a dose well within the comparable
MTD range in MS subjects.
3.2.4. Treatment with RTL1000 Did Not Induce Immuno-
suppression. Six subjects were evaluated for immunosup-
pression by assessment of cytokines and chemokines in
48h supernatants from anti-CD3 mAb-stimulated PBMC
cultures prior to and at 14d and 28d after infusion of
RTL1000 (three subjects receiving 200mg drug and two
receiving 60mg drug) or placebo (1 subject). No signiﬁcant
reduction was observed in the levels of any of the 12 factors
tested, including as examples, IL-6 and MIP-1α (Figure 4),
suggesting that a single infusion of RTL1000 did not induce
immunosuppression.
3.2.5. Treatment with RTL1000 Did Not Induce Signiﬁcant
Changes in Antibody Activity. ELISA evaluation of sera
collected post- versus pre-infusion revealed that the number
of MS subjects receiving any dose of RTL1000 who met the
criteria for increased levels of IgG and/or IgM antibody to
RTL1000 was not signiﬁcantly diﬀerent from the number
of antibody positive MS subjects receiving placebo (8/20
versus 2/11, P = 0.262). Of these, 2 of 8 subjects receiving
drug and 1 of 2 receiving placebo had increased antibody
responses to DR2, and none had antibody responses to
MOG-35-55 peptide. Moreover, the magnitude of IgG or
IgMantibodyreactivityafterinfusionversusbaselinewasnot
signiﬁcantly diﬀerent between the RTL1000 versus placebo-
treated groups (Supplementary Figure 1 available online at
doi:10.1155/2012/954739).
3.2.6. Pharmacokinetic Proﬁle of RTL1000. PK was deter-
mined on plasma from ﬁve subjects that received RTL1000
Mean clinical EAE score after a single treatment
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Figure 3: Mouse MOG homologue of RTL1000 treats EAE in
DR2 transgenic mice. HLA-DR2 mice were immunized with mouse
(m)MOG-35-55 peptide + CFA + Ptx to induce EAE and were
treated IV with a single dose of 100μg of the mouse (m)MOG
homologue of RTL1000 (DR2/mMOG-35-55 peptide) or buﬀer at
onset of clinical signs of EAE (indicated as Day 0, corresponding
to ∼Day 10 after immunization). The mice were scored daily for
28 days for clinical signs of EAE (n = 5 mice/group). Reduction
in daily scores and cumulative disease scores in RTL versus vehicle-
treated mice was signiﬁcant (∗P<0.05; †P<0.01, resp.). Inset.
Dose comparisons in mice versus humans based on body surface
area. Note that the 100μg dose that is highly eﬀective at treating
E A Ei nm i c ei se q u i v a l e n tt oa∼25mg dose in humans, well within
the safe dose range determined in our study. Figure reproduced in
part from Oﬀner et al. [23].
(two received 6mg; one, 100mg and two, 200mg). Subjects
receiving 6mg were infused over 60 minutes and subjects
receiving 100 and 200mg were infused over 120 minutes.
Blood plasma samples were collected prior to, during, and
after the infusion procedure and were evaluated for RTL1000
levels using sandwich ELISA. The concentration of RTL1000
in plasma is shown in Figure 5 for subjects receiving 6mg
of RTL1000 and for the subject receiving 100mg. Individual
linear regression parameters used to determine the RTL1000
half-lives could be derived in only ﬁve of the subjects
receiving active drug. RTL1000 was not detected in subjects
receiving placebo. Among the ﬁve patients receiving drug,
the mean ± SD half-life was 4.86 ± 2.04min with a range
of 2.73 to 7.04min. When the dose was increased from 20
to 60 to 200mg in Cohorts 3, 4, and 5, the mean Cmax
increased from 3.67 to 12.4 to 70.7ng/mL, respectively. Total
exposure (as assessed using AUClast) increased from 35 to
844to5090hr∗ng/mL,respectively.Thus,atthesethreedose
levels, a trend of increasing exposure as assessed by Cmax
and AUClast with dose was observed. Clearance (CL) and
volume of distribution could be assessed in only 3 patients
(from Cohorts 4 to 6). In these patients, CL ranged from
3250 to 44800mL/min and volume of distribution ranged
from 30.8 to 202liters. The very high clearance values are8 Autoimmune Diseases
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Figure 4: Treatment with RTL1000 did not induce immunosuppression. PBMC collected prior to and 14 and 28d after infusion of drug
fromtwosubjectsreceiving60mgdrug,threesubjectsreceiving200mgdrugandoneplacebosubjectwasevaluatedforlevelsofsecretedIL-6
(a) and MIP-1α (b) in supernatants collected 48h after stimulation with anti-CD3 mAb or in unstimulated Control cultures. No signiﬁcant
changes were observed at either postinfusion time point.
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Figure 5: Pharmacokinetic proﬁle of RTL1000. The mean concen-
tration of RTL1000 was assessed in plasma collected from study
subjects at the indicated times prior to and after IV infusion
of 6mg (Cohort 2) or 100mg (Cohort 6) RTL1000. Based on
these and other assessments (not shown), the half-life of RTL1000
was determined to be 4.86 ± 2.04min, with increasing exposure
(Cmax and AUClast) observed with increasing dose. Clearance
values ranging from 3250 to 44800mL/min were much greater
than hepatic blood ﬂow and indicate that RTL1000 was rapidly
eliminatedviaanonhepaticmechanism.Thehighnonphysiological
volumes of distribution ranging from 30.8 to 202liters indicate that
RTL1000 is tightly bound to sites not present in plasma.
much greater than hepatic blood ﬂow and indicate that
RTL1000 is rapidly eliminated via a nonhepatic mechanism.
The high nonphysiological volumes of distribution indicate
that RTL1000 is tightly bound to sites not present in plasma.
4. Discussion
This is the ﬁrst Phase 1 study of any recombinant T-cell
receptor ligand in humans. We found that a single infusion
of RTL1000 in HLA-DR2+ MS subjects was well tolerated
at doses of 60mg or less. Our study also found single
infusion of RTL1000 to be safe as there was no indication
of immunosuppression or liver enzyme abnormalities in the
treated subjects. Subjects receiving RTL1000 did not develop
signiﬁcant antibody responses against RTL1000, DR2 or
MOGpeptideandtherewasnoevidenceofdiseaseactivation
as detected clinically or by MRI. Importantly, an RTL1000
dose of 60mg in MS subjects is equivalent to ∼240μgi n
mice and administration of a single 100μg dose of a murine
RTL1000 homologue was highly eﬀective in treating EAE in
DR2 transgenic mice. Thus the maximum tolerated dose of
RTL1000 is in a therapeutic range based on EAE studies.
The homologues of RTL1000 designed to treat murine
EAE have a remarkable ability to rapidly reverse clinical
and histological signs of EAE without causing immunosup-
pression or toxicity. In a recent report [23], we reviewed
preclinical data showing the ability of RTLs to inhibit both
targeted cognate and bystander encephalitogenic Th1 and
Th17 T-cell speciﬁcities in DR2 transgenic [14, 20, 24],
C57BL/6 [16, 25], and SJL/J mice [15, 26]. Thus RTL treat-
ment is eﬀective in EAE models induced with three diﬀerent
myelin peptides and involving three diﬀerent MHC Class II
molecules. Importantly, RTLs block entry of inﬂammatory
cells into the CNS [16] and promote remyelination and
axonal regeneration in mice with chronic EAE [27, 28].
These studies provide compelling preclinical evidence that
RTL1000 therapy in MS has the potential to regulate both
MOG-35-55 peptide-speciﬁc and bystander T-cells of other
speciﬁcities,inhibitentryofinﬂammatorycellsintotheCNS,
and promote remyelination.
RTL1000 is an antigen speciﬁc therapy designed to
modulatethepathogenicinﬂammatoryresponseinMSwith-
out suppressing the immune system. Because it speciﬁcallyAutoimmune Diseases 9
modulates the immune system, the long-term safety proﬁle
of RTL1000 is likely to be better than that of monoclonal
antibodies, such as natalizumab, daclizumab and alem-
tuzumab, and small molecules, such as ﬁngolimod and clad-
ribine, that are immunosuppressive, cause profound lym-
phocytopenia or alter immunosurveillance within the CNS
[29–31]. Antigen speciﬁc therapies have the potential to
activate MS by stimulating pathogenic T cells as occurred
with an altered peptide ligand for MBP-83-99 [32]. We
did not observe disease activation in this Phase 1 trial
and believe activation is unlikely, as the unique RTL1000
construct ensures that MOG-35-55 peptide-speciﬁc T-cells
will interact with antigen in the absence of costimulatory
molecules. Other antigen-speciﬁc therapies, such as oral
myelin, intravenous MBP-82-98 peptide [33]a n da nM B P
DNA vaccine [34], have been assessed in MS and were
not eﬀective. We believe that RTL1000 is more likely to
prove eﬀective because its unique design renders it more
eﬃcient at modulating pathogenic immune responses than
free peptide or a DNA vaccine. Finally, unlike other antigen-
speciﬁc therapies, our preclinical studies in EAE suggest
that RTL1000 may promote remyelination. Thus RTL1000
represents a promising and novel therapy for MS.
The PK ofRTL1000 is ofinterest. PK analysisofRTL1000
revealed a dose-dependent increase in exposure and a short
half-life of ∼5min only for subjects receiving drug. These
data are remarkably similar to our preclinical studies in
mice that demonstrated a similar half-life (∼10min, data
not shown). The rapid half-life and clearance values and
the high nonphysiological volume of distribution suggest
that RTL1000 binds to cellular components in blood or
possibly to the vascular endothelium. In this regard, RTL
binding to mouse antigen-presenting cells inhibited T-cell
activation and transfer of EAE [35], and RTL1000 binding to
human platelets reduced platelet aggregation and prolonged
occlusive thrombus formation in blood [36]. Taken together,
these ﬁndings suggest that the rapid compartmentaliza-
tion of RTL1000 to circulating cells and platelets enables
inhibitoryactivity,whichmaybeimportanttoitstherapeutic
mechanism of action.
The study’s limitations include asmallsamplesize, inclu-
sion of a mixture of MS populations, that is, subjects with
relapsingremittingaswellassecondaryprogressivesubtypes,
and relatively short followup. We also only administered a
single infusion of RTL1000 and it is possible that disease
activation, development of antibodies against RTL1000, DR2
or MOG peptide or other side eﬀects might occur with
multiple dosing of RTL1000. We are currently planning to
test the safety and potential eﬃcacy of multiple monthly
infusions of RTL1000 in a Phase 2 trial.
Insummary,ourstudyshowsthatasingleIVadministra-
tion of RTL1000 is safe and well tolerated up to 60mg, a dose
that is comparable to a clinically eﬀective RTL dose in DR2
mice with EAE. Based on the extensive preclinical testing of
RTL in EAE, RTL1000 oﬀers the potential for controlling
inﬂammationwithoutcausingimmunosuppressionandmay
promote remyelination. Because of its rapid and sustained
anti-inﬂammatory eﬀects and based on the results obtained
in the EAE experiments of RTL, a single dose of RTL1000
might be eﬀective in treating relapses of MS. In addition,
evaluation of the safety and potential eﬃcacy of monthly
infusions of RTL1000 as a long-term treatment for MS may
also be warranted given its potent anti-inﬂammatory eﬀects
and apparent ability to promote repair in EAE.
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